AV nodal ablation and pacemaker implantation improves hemodynamic function in atrial fibrillation

PACE - Pacing and Clinical Electrophysiology

Volumn 26, Issue 5, 2003, Pages 1212-1217

  Takahashi, Yoshihide ^a,j   Yoshito, Iesaka ^a   Takahashi, Atsushi ^a   Harada, Tomoo ^b   Mitsuhashi, Takeshi ^c   Shirota, Kinya ^d   Kumagai, Koichiro ^e   Nuruki, Norihito ^f   Shiraishi, Takayoshi ^g   Nitta, Junichi ^h   Ito, Hiroshi ⁱ  

^a Tsuchiura Kyodo Hospital   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d MATSUE RED CROSS HOSPITAL   (Japan)

^e FUKUOKA UNIVERSITY   (Japan)

^f Shin Kogah Hospital   (Japan)

^g KAGOSHIMA UNIVERSITY   (Japan)

^h MUSASHINO RED CROSS HOSPITAL   (Japan)

ⁱ TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^j NONE   (Japan)

more..

Author keywords

Atrial fibrillation; Atrial natriuretic peptide; Brain natriuretic peptide; Catheter ablation; Pacemaker

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; ARTIFICIAL HEART PACEMAKER; CATHETER ABLATION; CLINICAL ARTICLE; ECHOCARDIOGRAPHY; HEART ATRIOVENTRICULAR NODE; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FUNCTION; HEMODYNAMICS; HUMAN; PATIENT SELECTION; PREDICTION; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; QUESTIONNAIRE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

AGED; ATRIAL FIBRILLATION; ATRIAL NATRIURETIC FACTOR; ATRIOVENTRICULAR NODE; CATHETER ABLATION; ECHOCARDIOGRAPHY; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PACEMAKER, ARTIFICIAL; QUALITY OF LIFE; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 0038066455     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1460-9592.2003.t01-1-00171.x     Document Type: Article

References (40)

1. Prystowsky EN, Benson W. Jr., Fuster V, et al. Management of patients with atrial fibrillation - A statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology, American Heart Association. Circulation 1996; 93:1262-1277.
2. Scheinman MM, Morady F, Hess DS, et al. Catheter-induced ablation of the atrioventricular junction to control refractory supraventricular arrhythmias. JAMA 1982; 248:851-855.
3. Gallagher JJ, Svenson RH, Kasell JH, et al. Catheter technique for closed-chest ablation of the atrioventricular conduction system: A therapeutic alternative for the treatment of refractory supraventricular tachycardia. N Engl J Med 1982; 306:194-200.
4. Evans GT Jr., Scheinman MM, Bardy G, et al. Predictors of inhospital mortality after DC catheter ablation of atrioventricular junction - Results of a prospective, international, multicenter study. Circulation 1991; 84: 1924-1937.
5. Langberg JJ, Chin MC, RosenqvistM, et al. Catheter ablation of the atrioventricular junction with radiofrequency energy. Circulation 1989; 80:1527-1535.
6. Morady F, Calkins H, Langberg JJ, et al. A prospective randomized comparison of direct current and radiofrequency ablation of the atrioventricular junction. J Am Coll Cardiol 1993; 21:102-109.
7. Olgin JE, Scheinman MM. Comparison of high energy direct current and radiofrequency catheter ablation of the atrioventricular junction. J Am Coll Cardiol 1993; 21:557-564.
8. Bringnole M, Gianfranchi L, Menozzi C, et al. Influence of atrioventricular junction radiofrequency ablation in patients with chronic atrial fibrillation and flutter on quality of life and cardiac performance. Am J Cardiol 1994; 74:242-246.
9. Bubien RS, Knotts-Dolson SM, Plumb VJ, et al. Effect of radiofrequency catheter ablation on health-related quality of life and activities of daily living in patients with recurrent arrhythmias. Circulation 1996; 94:1585-1591.
10. Fitzpatrick AP, Kourouyan HD, Siu A, et al. Quality of life and outcomes after radiofrequency His-bundle catheter ablation and permanent pacemaker implantation: Impact of treatment in paroxysmal and established atrial fibrillation. Am Heart J 1996; 131:499-507.
11. Bringnole M, Gianfranchi L, Menozzi C, et al. Assessment of atrioventricular junction ablation and DDDR mode-switching pacemaker versus pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation. A randomized controlled study. Circulation 1997; 96:2617-2624.
12. Bringnole M, Menozzi C, Gianfranchi L, et al. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation. A randomized, controlled study. Circulation 1998; 98:953-960.
13. Lee SH, Chen SA, Tai CT, et al. Comparison of quality of life and cardiac performance after complete atrioventricular junction ablation and atrioventricular junction modification in patients with medically refractory atrial fibrillation. J Am Coll Cardiol 1998; 31:637-644.
14. Natale A, Zimerman L, Tomassoni G, et al. AV node ablation and pacemaker implantation after withdrawal of effective rate-control medications for chronic atrial fibrillation: Effect on quality of life and exercise performance. PACE 1999; 22:1634-1639.
15. Marshall HJ, Harris ZI, Griffith MJ, et al. Prospective randomized study of ablation and pacing versus medical therapy for paroxysmal atrial fibrillation: effects of pacing mode and mode-switch algorithm. Circulation 1999; 99:1587-1592.
16. Wood MA, Brown-Mahoney C, Kay GN, et al. Clinical outcomes after ablation and pacing therapy for atrial fibrillation. A metaanalysis. Circulation 2000; 101:1138-1144.
17. Gillis AM, Connolly SJ, Lacombe P, et al. Randomized crossover comparison of DDDR versus VDD pacing after atrioventricular junction ablation for prevention of atrial fibrillation. Circulation 2000; 102:736-741.
18. Ueng KC, Tsai TP, Tsai CF, et al. Acute and long-term effects of atrioventricular junction ablation and VVIR pacemaker in symptomatic patients with chronic lone atrial fibrillation and normal ventricular response. J Cardiovasc Electrophysiol 2001; 12:303-309.
19. Ozcan C, Jahangir A, Friedman PA, et al. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med 2001; 344:1043-1051.
20. Burnett JC Jr., Kao PC, Hu DC, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986; 231:1145-1147.
21. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87:1402-1412.
22. Motwani JG, McAlpine H, Kennedy N, et al. Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet 1993; 341:1109-1113.
23. Choy AM, Darbar D, Lang CC, et al. Detection of left ventricular dysfunction after acute myocardial infarction: Comparison of clinical, echocardiographic, and neurohormonal methods. Br Heart J 1994; 72:16-22.
24. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 35:9-13.
25. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90:195-203.
26. Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomodullin. Circulation 1998; 97:1921-1929.
27. The WHO QOL group. Development of the World Health Organization WHOQOL-BREF Quality of Life Assessment. Psychological Medicine 1998; 28:551-558.
28. Knotts SM, Bubien RN, Miers L, et al. Is quality of life is improved by radiofrequency catheter ablation? A pilot study to assess measurable outcomes. (abstract) PACE 1994; 17:806.
29. Bubien RS, Packa DR, Karst G, et al. Does activity sensing rate adaptive pacing improve quality-of-life? (abstract) PACE 1989; 12:688.
30. Kay GN, Bubien RS, Karst GL. Metabolic versus activity sensors for rate-adaptive pacing: A prospective comparison utilizing quality of life measurements. (abstract) PACE 1989; 12:641.
31. Bubien RS, Kay GN. A randomized comparison of quality-of-life and exercise capacity with DDD and VVIR pacing modes. (abstract) PACE 1990; 13:524.
32. Bubien RS, Knotts SM, Plumb VJ, et al. Effect of radiofrequency catheter ablation on health-related quality of life and activities of daily living in patients with recurrent arrhythmias. Circulation 1996; 94:1585-1591.
33. Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: A reversible form of left ventricular dysfunction. Am J Cardiol 1986; 57:563-570.
34. Tomita M, Spinale FG, Crawford FA, et al. Changes in left ventricular volume, mass, and function during the development and regression of supraventricular tachycardia-induced cardiomyopathy. Disparity between recovery of systolic versus diastolic function. Circulation 1991; 83:635-644.
35. Daoud EG, Weiss R, Bahu M, et al. Effect of an irregular ventricular rhythm on cardiac output. Am J Cadiol 1996; 78:1433-1435.
36. Natale A, Zimerman L, Tomassoni G, et al. Impact on ventricular function and quality of life of transcatheter ablation of the atrioventricular junction in chronic atrial fibrillation with a normal ventricular response. Am J Cadiol 1996; 78:1431-1433.
37. Clark DM, Plumb VJ, Epstein AE, et al. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol 1997; 30:1039-1045.
38. Rossi A, Enriquez-Sarano M, Burnett JC Jr., et al. Natriuretic peptide levels in atrial fibrillation: A prospective hormonal and Dopplerechocardiographic study. J Am Coll Cardiol 2000; 35:1256-1262.
39. Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanism of atrial and brain natriuretic peptide release from rat ventricular myocardium: Effect of stretching. Endocrinology 1993; 132:1961-1970.
40. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355:1126-1130.